Financhill
Buy
71

CORT Quote, Financials, Valuation and Earnings

Last price:
$60.68
Seasonality move :
8.24%
Day range:
$59.25 - $64.66
52-week range:
$20.84 - $75.00
Dividend yield:
0%
P/E ratio:
48.27x
P/S ratio:
10.07x
P/B ratio:
9.29x
Volume:
2.1M
Avg. volume:
1M
1-year change:
147.83%
Market cap:
$6.3B
Revenue:
$675M
EPS (TTM):
$1.24

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CORT
Corcept Therapeutics
$200.1M $0.42 36.28% 84% $99.75
ACAD
ACADIA Pharmaceuticals
$273M $0.22 13.31% -5.76% $24.70
CPRX
Catalyst Pharmaceuticals
$134.2M $0.55 29.86% 137.22% $32.33
IONS
Ionis Pharmaceuticals
$139.2M -$0.84 5.02% -5.61% $59.72
NKTR
Nektar Therapeutics
$36.7M -$0.20 31.42% -18.18% $4.56
RIGL
Rigel Pharmaceuticals
$57.6M $0.58 32.49% 227.68% $32.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CORT
Corcept Therapeutics
$59.85 $99.75 $6.3B 48.27x $0.00 0% 10.07x
ACAD
ACADIA Pharmaceuticals
$19.33 $24.70 $3.2B 14.21x $0.00 0% 3.36x
CPRX
Catalyst Pharmaceuticals
$21.66 $32.33 $2.6B 16.53x $0.00 0% 5.50x
IONS
Ionis Pharmaceuticals
$31.33 $59.72 $5B -- $0.00 0% 6.64x
NKTR
Nektar Therapeutics
$0.80 $4.56 $146.9M -- $0.00 0% 1.72x
RIGL
Rigel Pharmaceuticals
$21.84 $32.00 $384.7M 94.96x $0.00 0% 2.43x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CORT
Corcept Therapeutics
-- 2.933 -- 3.11x
ACAD
ACADIA Pharmaceuticals
-- -0.276 -- 2.18x
CPRX
Catalyst Pharmaceuticals
-- 0.867 -- 4.83x
IONS
Ionis Pharmaceuticals
68.08% -0.170 22.73% 7.73x
NKTR
Nektar Therapeutics
-- -1.633 -- 3.65x
RIGL
Rigel Pharmaceuticals
132.43% 8.138 20.97% 1.69x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CORT
Corcept Therapeutics
$178.9M $25.3M 23.78% 23.78% 13.89% $59.2M
ACAD
ACADIA Pharmaceuticals
$237.8M $7M 41.59% 41.59% 2.69% $63.2M
CPRX
Catalyst Pharmaceuticals
$120.2M $62.8M 27.81% 27.81% 44.31% $70.8M
IONS
Ionis Pharmaceuticals
$222.7M -$110.8M -26.5% -103.27% -37.86% -$144.2M
NKTR
Nektar Therapeutics
$19.7M -$34.3M -154.23% -154.23% -128.62% -$44.6M
RIGL
Rigel Pharmaceuticals
$47.3M $14.1M 12% -- 26.18% $21.7M

Corcept Therapeutics vs. Competitors

  • Which has Higher Returns CORT or ACAD?

    ACADIA Pharmaceuticals has a net margin of 16.9% compared to Corcept Therapeutics's net margin of 55.37%. Corcept Therapeutics's return on equity of 23.78% beat ACADIA Pharmaceuticals's return on equity of 41.59%.

    Company Gross Margin Earnings Per Share Invested Capital
    CORT
    Corcept Therapeutics
    98.38% $0.26 $679.6M
    ACAD
    ACADIA Pharmaceuticals
    91.6% $0.86 $732.8M
  • What do Analysts Say About CORT or ACAD?

    Corcept Therapeutics has a consensus price target of $99.75, signalling upside risk potential of 66.67%. On the other hand ACADIA Pharmaceuticals has an analysts' consensus of $24.70 which suggests that it could grow by 27.78%. Given that Corcept Therapeutics has higher upside potential than ACADIA Pharmaceuticals, analysts believe Corcept Therapeutics is more attractive than ACADIA Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CORT
    Corcept Therapeutics
    2 0 0
    ACAD
    ACADIA Pharmaceuticals
    6 7 0
  • Is CORT or ACAD More Risky?

    Corcept Therapeutics has a beta of 0.583, which suggesting that the stock is 41.724% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.979%.

  • Which is a Better Dividend Stock CORT or ACAD?

    Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. ACADIA Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CORT or ACAD?

    Corcept Therapeutics quarterly revenues are $181.9M, which are smaller than ACADIA Pharmaceuticals quarterly revenues of $259.6M. Corcept Therapeutics's net income of $30.7M is lower than ACADIA Pharmaceuticals's net income of $143.7M. Notably, Corcept Therapeutics's price-to-earnings ratio is 48.27x while ACADIA Pharmaceuticals's PE ratio is 14.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 10.07x versus 3.36x for ACADIA Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CORT
    Corcept Therapeutics
    10.07x 48.27x $181.9M $30.7M
    ACAD
    ACADIA Pharmaceuticals
    3.36x 14.21x $259.6M $143.7M
  • Which has Higher Returns CORT or CPRX?

    Catalyst Pharmaceuticals has a net margin of 16.9% compared to Corcept Therapeutics's net margin of 39.44%. Corcept Therapeutics's return on equity of 23.78% beat Catalyst Pharmaceuticals's return on equity of 27.81%.

    Company Gross Margin Earnings Per Share Invested Capital
    CORT
    Corcept Therapeutics
    98.38% $0.26 $679.6M
    CPRX
    Catalyst Pharmaceuticals
    84.74% $0.44 $727.6M
  • What do Analysts Say About CORT or CPRX?

    Corcept Therapeutics has a consensus price target of $99.75, signalling upside risk potential of 66.67%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $32.33 which suggests that it could grow by 49.28%. Given that Corcept Therapeutics has higher upside potential than Catalyst Pharmaceuticals, analysts believe Corcept Therapeutics is more attractive than Catalyst Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CORT
    Corcept Therapeutics
    2 0 0
    CPRX
    Catalyst Pharmaceuticals
    7 0 0
  • Is CORT or CPRX More Risky?

    Corcept Therapeutics has a beta of 0.583, which suggesting that the stock is 41.724% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.796, suggesting its less volatile than the S&P 500 by 20.403%.

  • Which is a Better Dividend Stock CORT or CPRX?

    Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CORT or CPRX?

    Corcept Therapeutics quarterly revenues are $181.9M, which are larger than Catalyst Pharmaceuticals quarterly revenues of $141.8M. Corcept Therapeutics's net income of $30.7M is lower than Catalyst Pharmaceuticals's net income of $55.9M. Notably, Corcept Therapeutics's price-to-earnings ratio is 48.27x while Catalyst Pharmaceuticals's PE ratio is 16.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 10.07x versus 5.50x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CORT
    Corcept Therapeutics
    10.07x 48.27x $181.9M $30.7M
    CPRX
    Catalyst Pharmaceuticals
    5.50x 16.53x $141.8M $55.9M
  • Which has Higher Returns CORT or IONS?

    Ionis Pharmaceuticals has a net margin of 16.9% compared to Corcept Therapeutics's net margin of -46.06%. Corcept Therapeutics's return on equity of 23.78% beat Ionis Pharmaceuticals's return on equity of -103.27%.

    Company Gross Margin Earnings Per Share Invested Capital
    CORT
    Corcept Therapeutics
    98.38% $0.26 $679.6M
    IONS
    Ionis Pharmaceuticals
    98.31% -$0.66 $1.8B
  • What do Analysts Say About CORT or IONS?

    Corcept Therapeutics has a consensus price target of $99.75, signalling upside risk potential of 66.67%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $59.72 which suggests that it could grow by 90.61%. Given that Ionis Pharmaceuticals has higher upside potential than Corcept Therapeutics, analysts believe Ionis Pharmaceuticals is more attractive than Corcept Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CORT
    Corcept Therapeutics
    2 0 0
    IONS
    Ionis Pharmaceuticals
    13 7 0
  • Is CORT or IONS More Risky?

    Corcept Therapeutics has a beta of 0.583, which suggesting that the stock is 41.724% less volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.345, suggesting its less volatile than the S&P 500 by 65.483%.

  • Which is a Better Dividend Stock CORT or IONS?

    Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CORT or IONS?

    Corcept Therapeutics quarterly revenues are $181.9M, which are smaller than Ionis Pharmaceuticals quarterly revenues of $226.6M. Corcept Therapeutics's net income of $30.7M is higher than Ionis Pharmaceuticals's net income of -$104.3M. Notably, Corcept Therapeutics's price-to-earnings ratio is 48.27x while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 10.07x versus 6.64x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CORT
    Corcept Therapeutics
    10.07x 48.27x $181.9M $30.7M
    IONS
    Ionis Pharmaceuticals
    6.64x -- $226.6M -$104.3M
  • Which has Higher Returns CORT or NKTR?

    Nektar Therapeutics has a net margin of 16.9% compared to Corcept Therapeutics's net margin of -153.61%. Corcept Therapeutics's return on equity of 23.78% beat Nektar Therapeutics's return on equity of -154.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    CORT
    Corcept Therapeutics
    98.38% $0.26 $679.6M
    NKTR
    Nektar Therapeutics
    81.62% -$0.18 $48.9M
  • What do Analysts Say About CORT or NKTR?

    Corcept Therapeutics has a consensus price target of $99.75, signalling upside risk potential of 66.67%. On the other hand Nektar Therapeutics has an analysts' consensus of $4.56 which suggests that it could grow by 472.72%. Given that Nektar Therapeutics has higher upside potential than Corcept Therapeutics, analysts believe Nektar Therapeutics is more attractive than Corcept Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CORT
    Corcept Therapeutics
    2 0 0
    NKTR
    Nektar Therapeutics
    2 3 0
  • Is CORT or NKTR More Risky?

    Corcept Therapeutics has a beta of 0.583, which suggesting that the stock is 41.724% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 0.576, suggesting its less volatile than the S&P 500 by 42.402%.

  • Which is a Better Dividend Stock CORT or NKTR?

    Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CORT or NKTR?

    Corcept Therapeutics quarterly revenues are $181.9M, which are larger than Nektar Therapeutics quarterly revenues of $24.1M. Corcept Therapeutics's net income of $30.7M is higher than Nektar Therapeutics's net income of -$37.1M. Notably, Corcept Therapeutics's price-to-earnings ratio is 48.27x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 10.07x versus 1.72x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CORT
    Corcept Therapeutics
    10.07x 48.27x $181.9M $30.7M
    NKTR
    Nektar Therapeutics
    1.72x -- $24.1M -$37.1M
  • Which has Higher Returns CORT or RIGL?

    Rigel Pharmaceuticals has a net margin of 16.9% compared to Corcept Therapeutics's net margin of 22.46%. Corcept Therapeutics's return on equity of 23.78% beat Rigel Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CORT
    Corcept Therapeutics
    98.38% $0.26 $679.6M
    RIGL
    Rigel Pharmaceuticals
    85.49% $0.70 $45.1M
  • What do Analysts Say About CORT or RIGL?

    Corcept Therapeutics has a consensus price target of $99.75, signalling upside risk potential of 66.67%. On the other hand Rigel Pharmaceuticals has an analysts' consensus of $32.00 which suggests that it could grow by 46.52%. Given that Corcept Therapeutics has higher upside potential than Rigel Pharmaceuticals, analysts believe Corcept Therapeutics is more attractive than Rigel Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CORT
    Corcept Therapeutics
    2 0 0
    RIGL
    Rigel Pharmaceuticals
    1 4 0
  • Is CORT or RIGL More Risky?

    Corcept Therapeutics has a beta of 0.583, which suggesting that the stock is 41.724% less volatile than S&P 500. In comparison Rigel Pharmaceuticals has a beta of 1.338, suggesting its more volatile than the S&P 500 by 33.834%.

  • Which is a Better Dividend Stock CORT or RIGL?

    Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Rigel Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CORT or RIGL?

    Corcept Therapeutics quarterly revenues are $181.9M, which are larger than Rigel Pharmaceuticals quarterly revenues of $55.3M. Corcept Therapeutics's net income of $30.7M is higher than Rigel Pharmaceuticals's net income of $12.4M. Notably, Corcept Therapeutics's price-to-earnings ratio is 48.27x while Rigel Pharmaceuticals's PE ratio is 94.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 10.07x versus 2.43x for Rigel Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CORT
    Corcept Therapeutics
    10.07x 48.27x $181.9M $30.7M
    RIGL
    Rigel Pharmaceuticals
    2.43x 94.96x $55.3M $12.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

New Billion Dollar Contract Surprises GEO Analysts
New Billion Dollar Contract Surprises GEO Analysts

While earnings appeared mixed at first glance, management’s comments on…

Is Visa a Long-term Buy Now?
Is Visa a Long-term Buy Now?

There is something inherently attractive about buying a stock and…

Should You Sell Home Depot Before It’s Too Late?
Should You Sell Home Depot Before It’s Too Late?

The housing market is not out of the woods just…

Stock Ideas

Buy
58
Is AAPL Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 39x

Sell
46
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
60
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
63
ROOT alert for Feb 28

Root [ROOT] is up 9.54% over the past day.

Sell
21
AAON alert for Feb 28

AAON [AAON] is down 3.2% over the past day.

Sell
34
ECPG alert for Feb 28

Encore Capital Group [ECPG] is down 8.57% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock